Application of recombinant thioredoxin1 for treatment of heart disease

Shouji Matsushima, Daniela Zablocki, Junichi Sadoshima

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)


Thioredoxin 1 (Trx1) is a small molecule with reactive cysteines that reduces proteins with disulfide bonds through a thiol disulfide exchange reaction. Accumulating lines of evidence suggest that Trx1 protects the heart from ischemia/reperfusion injury, pathological hypertrophy, and inflammation; induces preconditioning effects and angiogenesis; and upregulates mitochondrial genes. Exogenously given recombinant Trx1 (r-Trx1) may protect the heart through its actions in both extracellular and intracellular spaces. In this brief review, the potential of Trx1 therapy for heart disease is discussed. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure.".

Original languageEnglish
Pages (from-to)570-573
Number of pages4
JournalJournal of Molecular and Cellular Cardiology
Issue number4
Publication statusPublished - Oct 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Application of recombinant thioredoxin1 for treatment of heart disease'. Together they form a unique fingerprint.

Cite this